Crossmark

ACSL1: A preliminary study that provides a new target for the treatment of renal fibrosis could bring new insights in diabetic kidney disease

Crossref DOI link: https://doi.org/10.1016/j.nefroe.2023.05.008

Published Print: 2023-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Cao, Zhonghui

Gao, Xiao

Meng, Jing

Guo, Xiaoli

Xu, Jiahao

Cui, Junchao

Zhou, Xueyan https://orcid.org/0000-0002-3824-943X
Funding

Funding for this research was provided by:

Jiangsu Provincial Commission of Health and Family Planning (H2017079)

Science and Technology Planning Project of Guangdong Province (BE2019636)

National Natural Science Foundation of China (82173883)

Natural Science Research of Jiangsu Higher Education Institutions of China (18KA350002)

Natural Science Foundation of Jiangsu Province (BK20181470)
License Information

Text and Data Mining valid from 2023-12-01

Text and Data Mining valid from 2023-12-01

Version of Record valid from 2023-05-10
More Information

This article is maintained by: Elsevier

Article Title: ACSL1: A preliminary study that provides a new target for the treatment of renal fibrosis could bring new insights in diabetic kidney disease

Journal Title: Nefrología (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.nefroe.2023.05.008

Content Type: article

Copyright: © 2023 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U.